AIM:TRX

Stock Analysis Report

Executive Summary

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Risks

  • Tissue Regenix Group has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Tissue Regenix Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.3%

AIM:TRX

-0.1%

GB Biotechs

-1.1%

GB Market


1 Year Return

-52.7%

AIM:TRX

22.9%

GB Biotechs

-5.7%

GB Market

TRX underperformed the Biotechs industry which returned 22.9% over the past year.

TRX underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -5.3% over the past year.


Share holder returns

TRXIndustryMarket
7 Day1.3%-0.1%-1.1%
30 Day-12.4%1.9%-4.4%
90 Day-33.9%1.8%-2.7%
1 Year-52.7%-52.7%23.8%22.9%-1.3%-5.7%
3 Year-81.0%-81.0%12.1%10.2%17.6%3.9%
5 Year-86.1%-86.1%54.2%50.6%26.8%0.1%

Price Volatility Vs. Market

How volatile is Tissue Regenix Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tissue Regenix Group undervalued based on future cash flows and its price relative to the stock market?

1.36x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Tissue Regenix Group to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Tissue Regenix Group to establish if it is available at substantial discount.


Price Based on Earnings

Tissue Regenix Group is loss making, we can't compare its value to the GB Biotechs industry average.

Tissue Regenix Group is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Tissue Regenix Group, we can't assess if its growth is good value.


Price Based on Value of Assets

Tissue Regenix Group is good value based on assets compared to the GB Biotechs industry average.


Next Steps

Future Growth

How is Tissue Regenix Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

37.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Tissue Regenix Group's revenue is expected to grow significantly at over 20% yearly.

Tissue Regenix Group is not considered high growth as it is expected to be loss making for the next 1-3 years.

Tissue Regenix Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Unable to compare Tissue Regenix Group's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Tissue Regenix Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Tissue Regenix Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Tissue Regenix Group performed over the past 5 years?

-6.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Tissue Regenix Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Tissue Regenix Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Tissue Regenix Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Tissue Regenix Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Tissue Regenix Group has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Tissue Regenix Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Tissue Regenix Group's financial position?


Financial Position Analysis

Tissue Regenix Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Tissue Regenix Group's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Tissue Regenix Group has no debt.

Tissue Regenix Group has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Tissue Regenix Group has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Tissue Regenix Group has sufficient cash runway for 1.1 years based on current free cash flow.

Tissue Regenix Group has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -9.6% each year.


Next Steps

Dividend

What is Tissue Regenix Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Tissue Regenix Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Tissue Regenix Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Tissue Regenix Group has not reported any payouts.

Unable to verify if Tissue Regenix Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Tissue Regenix Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Tissue Regenix Group's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average board tenure


CEO

Gareth Jones (50yo)

0.0yrs

Tenure

UK£179,134

Compensation

Mr. Gareth Hywel Jones has been an Interim Chief Executive Officer of Tissue Regenix Group plc since August 1, 2019 and serves as its Chief Operating Officer. He has been Company Secretary of Tissue Regeni ...


CEO Compensation Analysis

Gareth's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Insufficient data for Gareth to compare compensation growth.


Board Age and Tenure

3.1yrs

Average Tenure

52yo

Average Age

The tenure for the Tissue Regenix Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • John Andrew Samuel (67yo)

    Executive Chairman

    • Tenure: 1.8yrs
    • Compensation: UK£111.00k
  • Daniel Lee

    President of US Operations

    • Tenure: 0.6yrs
  • Joel Pickering

    President of TRX BioSurgery

    • Tenure: 2.6yrs
  • Gareth Jones (50yo)

    Interim CEO

    • Tenure: 0.0yrs
    • Compensation: UK£179.13k
  • Caitlin Pearson

    Head of Communications

    • Tenure: 0.0yrs
  • Eileen Ingham

    Consultant

    • Tenure: 0.0yrs

Board Members

  • Jon Glenn (50yo)

    Non-Executive Director

    • Tenure: 3.6yrs
    • Compensation: UK£30.00k
  • John Andrew Samuel (67yo)

    Executive Chairman

    • Tenure: 1.8yrs
    • Compensation: UK£111.00k
  • Alan Jonathan Miller (54yo)

    Non-Executive Director

    • Tenure: 9.2yrs
    • Compensation: UK£35.00k
  • Shervanthi Homer-Vanniasinkam

    Non- Executive Director

    • Tenure: 3.2yrs
    • Compensation: UK£30.00k
  • Gareth Jones (50yo)

    Interim CEO

    • Tenure: 0.0yrs
    • Compensation: UK£179.13k
  • Randeep Grewal

    Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: UK£35.00k
  • Steven Arnoczky

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.1yrs
  • David Caborn

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.1yrs
  • Thomas Carter

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.1yrs
  • Philip Davidson

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.1yrs

Company Information

Tissue Regenix Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tissue Regenix Group plc
  • Ticker: TRX
  • Exchange: AIM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£45.078m
  • Shares outstanding: 1.16b
  • Website: https://www.tissueregenix.com

Number of Employees


Location

  • Tissue Regenix Group plc
  • Unit 1 & 2
  • Astley Way
  • Leeds
  • West Yorkshire
  • LS26 8XT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJun 2010
TSSN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2010

Biography

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and international ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 21:22
End of Day Share Price2019/08/20 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.